Postsurgery Recurrent Carcinoma Cervix
Conditions
Keywords
recurrent carcinoma cervix, Vault carcinoma, Tomotherapy, Brachytherapy
Brief summary
Radiotherapy is the most appropriate treatment for postoperative recurrent carcinoma cervix. However it is technically difficult to deliver adequate doses of RT due to presence of small intestines in the radiation area; thus disease control rates are poor and complication rates are high with conventional radiotherapy. Use of IMRT and brachytherapy for these cases allows for increasing dose to the tumor while sparing normal structures. It is expected that the use of a combination of IMRT & brachytherapy will achieve higher disease control rates and decrease the complication rates.
Detailed description
SPECIFIC OBJECTIVES: 1. To evaluate the efficacy of combination of intensity-modulated radiotherapy (IMRT) and brachytherapy in delivering dose escalated radiotherapy in postoperative residual / recurrent cases of carcinoma cervix, in terms of local control proportion and progression free survival (PFS) 2. To study the late and acute toxicities associated with this treatment. 3. Dosimetric comparison of Tomotherapy and conventional IMRT DESIGN: Prospective, phase II study. STUDY POPULATION: All patients of age \< 65 years diagnosed with postsurgery recurrent squamous cell carcinoma cervix without previous history of radiotherapy. STUDY SIZE: 90 patients METHODOLOGY: Ninety cases of cervical cancer with postsurgery recurrence limited to the pelvis will be screened and taken for study if eligible after taking the informed consent. Patients will receive external radiation therapy using IMRT to pelvis with additional dose of localized radiotherapy boost with brachytherapy to the vault with weekly concurrent chemotherapy. The local recurrence rate and 5 year disease free survival rate of all the patients will be studied. PROJECT PERIOD: Total project period : 5 years Recruitment, Data collection : 4 years Complete analysis of data : 1 year STUDY SITE: Tata memorial centre
Interventions
RADIATIONRadiotherapy
Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations. Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions.
Sponsors
Tata Memorial Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
. Only histologically proven postoperative recurrence of squamous carcinoma of cervix following hysterectomy \>3 months without adjuvant treatment * Patients below 65 years of age and with KPS \>70%. * Patients with disease confined to the pelvis, based on CT/MRI/PET Scan * Normal ECG and cardiovascular system * Normal hematological parameters * Normal renal and liver function tests
Exclusion criteria
* Previous chemotherapy or radiotherapy to the pelvis * Pelvic LN \>3cm in size * Presence of disease outside the pelvis (Paraortic nodes, distant metastasis) * Bilateral hydronephrosis * Co-morbid conditions like uncontrolled Diabetes Mellitus or medical renal disease * Medical or Psychological condition that would preclude treatment * Patient unreliable for treatment and follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the utility of intensity-modulated radiotherapy (IMRT) in delivering dose escalated radiotherapy in postoperative recurrent cases of carcinoma cervix, in terms of local control | 3 Years | Progression free survival of all patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To study the late toxicities associated with this treatment | 3 Years | Side effects of radiotherapy and chemotherapy will be recorded at baseline, during treatment, at 6 and 12 months and annually thereafter according to the RTOG scales |
Countries
India
Contacts
Primary ContactReena Engineer, MD
Backup ContactShyamKishore Shrivastava, MD
Outcome results
None listed